Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

(OP:PMBHF)

N/A UNCHANGED
Last Price Updated: 9:46 AM EST, Jan 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about PMBHF

News headline image
Psychedelics Headlines: MDMA & Coping Skills In PTSD, LSD's Perceived Risks, Knowledge Gaps, Surveys & More ↗
Welcome to Benzinga's weekly psychedelics headlines roundup. This is our pick of must-read news items from the second week of January 2024.  
Via Benzinga
News headline image
Psychedelics Headlines: Magic Mushrooms For Sexual Wellbeing, The DEA's Stance, The Therapist's Role & More ↗
Welcome to Benzinga's weekly psychedelics news roundup. We have pulled together several must-read news items from the last week of December 2023 and the first of January 2024.  
Via Benzinga
News headline image
PharmAla-1 Molecule Receives US Patent Prosecution Highway Acceptance
PharmAla to present its intellectual property assets to potential partners at the annual JPM healthcare conference on January 8-11th in San Francisco 
From PharmAla Biotech
Via GlobeNewswire
News headline image
Canada To Australia: New MDMA & Psilocybin Shipment On Its Way For Legal Therapeutic Market ↗
The first of several of PharmAla Biotech’s (OTC: PMBHF) shipments of psychedelic molecules -both API and finished drug product capsules- to its Australian JV Cortexa for use under the Authorized... 
Via Benzinga
News headline image
PharmAla Begins Trading on OTCQB
From PharmAla Biotech
Via GlobeNewswire
News headline image
Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More ↗
First Ever Professional Practice Guidelines For Psychedelic-Assisted Therapy Published 
Via Benzinga
News headline image
Psyched: Portugal Decriminalizes Synthetic Drugs, Anorexia And Psilocybin, LSD Microdosing, California & More ↗
A Revolutionary Approach: Portugal Decriminalizes Synthetic Drugs Portugal’s Parliament recently decriminalized the use of synthetic drugs. The new law equates the legal treatment of these substances... 
Via Benzinga
News headline image
PharmAla Files IP Protection For Novel MDXX Molecule: Viability As Autism Spectrum Treatment ↗
Canadian biotech company PharmAla Biotech Holdings (OTC: PMBHF) has filed a patent covering composition of matter of Novel Chemical Entity (NCE) PharmAla-1.  
Via Benzinga
News headline image
PharmAla Files Patent for Novel MDXX Molecule PharmAla-1
Patent Filing Follows Year of Preclinical Research, Academic Publication 
From PharmAla Biotech
Via GlobeNewswire
News headline image
Cybin, Bright Minds And PharmAla: A Short Recap On Progress Within Clinical Trials ↗
Cybin One Steps Away From Complete Dosing 
Via Benzinga
News headline image
Psyched: Australia's Innovative Program, Congressional Amendments, Therapy Reimbursement And More ↗
First Country Allowing MDMA & Psilocybin For Depression, PTSD Makes Headlines On Saturday, July 1, 2023, Australia became the first country to allow physicians to prescribe MDMA to treat post-traumatic... 
Via Benzinga
News headline image
PharmAla's Australian JV Cortexa Orders First Commercial MDMA & Psilocybin Shipment ↗
As Australia’s psychedelic program launches, PharmAla Biotech Holdings Inc.’s (OTC: PMBHF) new 
Via Benzinga
News headline image
Life Science Investor Forum: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Life Science Investor Forum Agenda Announced for June 22nd
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
MDMA Deals: Optimi Supplies Numinus-MAPS Program & PharmAla Exports To Australian University ↗
Numinus Wellness (OTCMKTS: NUMIF) with support from the Multidisciplinary Association for Psychedelic Studies (MAPS) will utilize Optimi Health’s (OTCMKTS: OPTHF) Good Manufacturing Practice... 
Via Benzinga
News headline image
Canadian Financing: PharmAla Biotech Offers Non-Brokered Private Placement Up To $3.76M ↗
MDXX-class molecules biotech company PharmAla Biotech Holdings Inc. (OTCMKTS: PMBHF) has announced a non-brokered private placement of a minimum of 3.3 million units and a maximum of 16.6 million of... 
Via Benzinga
News headline image
Promising Milestone: FDA Approves California-Based Trial Assessing MDMA For Schizophrenia ↗
The FDA has approved a clinical trial that will assess PharmAla Biotech Holdings' (OTC: PMBHF) proprietary LaNeo Investigational Medical Product (IMP) 40mg MDMA capsules for the treatment of... 
Via Benzinga
News headline image
USFDA Approves LaNeo MDMA for Clinical Trial Use in the United States
From PharmAla Biotech
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.